Stefan K. Barta, MD, MS
Associate Professor of Clinical Medicine (Hematology-Oncology)
Director, T-cell Lymphoma Program, UPenn
Department: Medicine
Contact information
Perelman Center
12th Floor, Room 12-177
3400 Civic Center Blvd
Philadelphia, PA 19104
12th Floor, Room 12-177
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 2156156506
Fax: 2156155887
Fax: 2156155887
Education:
MD (Medicine)
Johann-Wolfgang Goethe University , 1999.
MS (Clinical Research Methods)
Albert Einstein College of Medicine , 2011.
Permanent linkMD (Medicine)
Johann-Wolfgang Goethe University , 1999.
MS (Clinical Research Methods)
Albert Einstein College of Medicine , 2011.
Description of Clinical Expertise
T-cell lymphomas; HIV-associated lymphomas; Cutaneous lymphomasDescription of Research Expertise
HIV related lymphomas; T-cell lymphomas; Cutaneous lymphomas.Selected Publications
Elghawy O, Wang J, Leung OJ, Swami N, Carvajal V, Yang G, Landsburg DJ, Svoboda J, Nasta SD, Chong EA, Schuster SJ, Thomas CJ, Carter JS, Bagg A, Barta SK.: Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience. Clin Lymphoma Myeloma Leuk Feb 2025.Thomas CJ, Porter D, Van Deerlin VM, Bhattacharyya S, Carvajal V, Kim J, Priore S, Yang G, Gerson JN, Barta SK.: Aleukemic soft-tissue relapse post allogeneic hematopoietic cell transplantation in T-prolymphocytic leukemia. Leuk Lymphoma Feb 2025.
Danilov AV, Sauter C, Phillips T, Coombs CC, Ip A, Wang Y, Rhodes J, Leslie L, Barrientos J, Saeed H, Strati P, Barta SK, Shadman M.: Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Clin Lymphoma Myeloma Leuk Jan 2025.
Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ.: Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy. Transplant Cell Ther Jan 2025.
Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Retrospective Cohort Study of Novel Oral Agents Lenalidomide and Duvelisib For Relapsed or Refractory Mycosis Fungoides and Sézary Syndrome. J Am Acad Dermatol Nov 2024.
Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ.: Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP. Haematologica Nov 2024.
Epperla N, Huang Y, Cashen AF, Vaughn JL, Hanel W, Badar T, Barta SK, Caimi PF, Sethi TK, Reddy N, Karmali R, Bello C, Chavez JC, Kothari SK, Hernandez-Ilizaliturri FJ, Svoboda J, Lansigan F, Glenn MJ, Cohen JB, Sorge C, Christian B, Herrera AF, Hamadani M, Costa LJ, Xavier AC.: Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Adv 8: 5458-5466, Nov 2024.
Landsburg DJ, Morrissette JJD, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Barlev A, Bagg A, Priore SF.: Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression. Cancer Res Commun 4: 2947-2954, Nov 2024.
Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, Córdoba R, Kusumoto S, Bachy E, Cwynarski K, Gritti G, Prica A, Jacobsen E, Feldman T, Guillermin Y, Ennishi D, Yoon DH, Domenech ED, Zain J, Wang J, Kim JS, Poel MV, Jin J, Wu S, Chen Y, Moriyama T, Inoue A, Nakajima K, Horwitz SM.: Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol Oct 2024.
Grover NS, Annunzio K, Watkins M, Torka P, Karmali R, Anampa-Guzmán A, Oh TS, Reves H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, Olszewski AJ, Epperla N.: Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study. Blood Cancer J 14: 182, Oct 2024.